Liquidia (LQDA) News Today

Liquidia Corporation (NASDAQ: LQDA) shares have decreased sharply after a Delaware federal court ruled that two claims of United Therapeutics’ ’327 patent are valid and infringed by YUTREPIA, Liquidia’s inhaled treprostinil product.

• Positive Sentiment: Liquidia plans to appeal the ruling and intends to seek removal of the PH-ILD indication from YUTREPIA’s label, potentially allowing the product to remain available for pulmonary arterial hypertension. The court also found the other four asserted patent claims invalid. Liquidia litigation update
• Positive Sentiment: Needham lowered its price target to $72 from $110 but maintained a “buy” rating, implying substantial upside if Liquidia successfully preserves YUTREPIA commercialization. Liquidia stock and analyst update
• Positive Sentiment: Before the ruling, YUTREPIA’s launch was driving rapid growth: Liquidia reported approximately $171.7 million in second-quarter 2026 revenue, up more than 1,800% year over year, supporting the company’s operating and cash-flow outlook.
• Neutral Sentiment: The court directed both sides to submit proposed remedies within one week. The eventual outcome could range from removing PH-ILD from YUTREPIA’s label to broader restrictions, and the appeal process could materially change the commercial impact. Reuters report on the patent ruling
• Negative Sentiment: The valid infringement finding threatens YUTREPIA’s PH-ILD business and raises the possibility of an injunction limiting product availability. That could reduce sales, weaken Liquidia’s growth case and give United Therapeutics’ competing Tyvaso products greater protection. United Therapeutics patent dispute report

The immediate investor focus is on the remedy and appeal: Liquidia’s strong YUTREPIA revenue momentum is being weighed against significant legal uncertainty surrounding its key product.